Nielk
Senior Member
- Messages
- 6,970
Hemispherx gets patent for Ampligen as flu vaccine enhancer
Published: July 19, 2011
Hemispherx Biopharma said Tuesday it was granted a patent from the U.S. Patent Office covering the use of its drug candidate Ampligen as a vaccine adjuvant for use with seasonal influenza vaccine.
View full article
Hemispherx Biopharma said Tuesday it was granted a patent from the U.S. Patent Office covering the use of its drug candidate Ampligen as a vaccine adjuvant for use with seasonal influenza vaccine.
The Philadelphia biotechnology company thinks Ampligen can be used to induce an enhanced immune response against H5N1 avian influenza.
Hemispherx (NYSE Amex:HEB) recently received Food and Drug Administration authorization to conduct a clinical trial to evaluate the breadth of immunological protection in healthy volunteers using Ampligen.
The company has spent more than three decades developing Ampligen as a potential treatment for chronic fatigue syndrome. Hemispherx is in the process of responding to questions the FDA raised about the companys new drug application, filed two years ago, seeking approval to market Ampligen for chronic fatigue patients.
Published: July 19, 2011
Hemispherx Biopharma said Tuesday it was granted a patent from the U.S. Patent Office covering the use of its drug candidate Ampligen as a vaccine adjuvant for use with seasonal influenza vaccine.
View full article
Hemispherx Biopharma said Tuesday it was granted a patent from the U.S. Patent Office covering the use of its drug candidate Ampligen as a vaccine adjuvant for use with seasonal influenza vaccine.
The Philadelphia biotechnology company thinks Ampligen can be used to induce an enhanced immune response against H5N1 avian influenza.
Hemispherx (NYSE Amex:HEB) recently received Food and Drug Administration authorization to conduct a clinical trial to evaluate the breadth of immunological protection in healthy volunteers using Ampligen.
The company has spent more than three decades developing Ampligen as a potential treatment for chronic fatigue syndrome. Hemispherx is in the process of responding to questions the FDA raised about the companys new drug application, filed two years ago, seeking approval to market Ampligen for chronic fatigue patients.